These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 27708433)
21. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes. Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603 [TBL] [Abstract][Full Text] [Related]
22. Immunization with Human Papillomavirus 16 L1+E2 Chimeric Capsomers Elicits Cellular Immune Response and Antitumor Activity in a Mouse Model. López-Toledo G; Schädlich L; Alonso-Castro ÁJ; Monroy-García A; García-Rocha R; Guido MC; Gissmann L; García-Carrancá A Viral Immunol; 2016 Jun; 29(5):276-87. PubMed ID: 27058179 [TBL] [Abstract][Full Text] [Related]
23. Genetic variability and lineage phylogeny of human papillomavirus type-16 and -53 based on the E6, E7, and L1 genes in Southwest China. Cao M; Chenzhang Y; Ding X; Zhang Y; Jing Y; Chen Z Gene; 2016 Oct; 592(1):49-59. PubMed ID: 27450917 [TBL] [Abstract][Full Text] [Related]
24. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Christensen ND; Dillner J; Eklund C; Carter JJ; Wipf GC; Reed CA; Cladel NM; Galloway DA Virology; 1996 Sep; 223(1):174-84. PubMed ID: 8806551 [TBL] [Abstract][Full Text] [Related]
25. Efficacy of DNA vaccines forming e7 recombinant retroviral virus-like particles for the treatment of human papillomavirus-induced cancers. Lescaille G; Pitoiset F; Macedo R; Baillou C; Huret C; Klatzmann D; Tartour E; Lemoine FM; Bellier B Hum Gene Ther; 2013 May; 24(5):533-44. PubMed ID: 23521528 [TBL] [Abstract][Full Text] [Related]
26. Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers. Orozco JJ; Carter JJ; Koutsky LA; Galloway DA J Virol; 2005 Aug; 79(15):9503-14. PubMed ID: 16014913 [TBL] [Abstract][Full Text] [Related]
27. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach. Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA Virol J; 2015 Sep; 12():140. PubMed ID: 26362430 [TBL] [Abstract][Full Text] [Related]
28. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression. Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747 [TBL] [Abstract][Full Text] [Related]
29. Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer. Baek JO; Seo JW; Kwon O; Park SM; Kim CH; Kim IH Enzyme Microb Technol; 2012 Mar; 50(3):173-80. PubMed ID: 22305172 [TBL] [Abstract][Full Text] [Related]
30. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice. Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312 [TBL] [Abstract][Full Text] [Related]
31. [Anti-peptide antibodies specifically recognize the L1 protein of human papilloma virus type 31]. Andreev SM; Giliazova AV; Khaitov MR; Kozlov DG Bioorg Khim; 2012; 38(6):667-75. PubMed ID: 23547470 [TBL] [Abstract][Full Text] [Related]
32. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909 [TBL] [Abstract][Full Text] [Related]
33. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Bartkowiak T; Singh S; Yang G; Galvan G; Haria D; Ai M; Allison JP; Sastry KJ; Curran MA Proc Natl Acad Sci U S A; 2015 Sep; 112(38):E5290-9. PubMed ID: 26351680 [TBL] [Abstract][Full Text] [Related]
34. Variations of human papillomavirus type 58 E6, E7, L1 genes and long control region in strains from women with cervical lesions in Liaoning province, China. Liu JH; Lu ZT; Wang GL; Zhou WQ; Liu C; Yang LX; Sun ZR; Ruan Q Infect Genet Evol; 2012 Oct; 12(7):1466-72. PubMed ID: 22659102 [TBL] [Abstract][Full Text] [Related]
35. Human papillomavirus type 16 variant analysis of E6, E7, and L1 genes and long control region in biopsy samples from cervical cancer patients in north India. Pande S; Jain N; Prusty BK; Bhambhani S; Gupta S; Sharma R; Batra S; Das BC J Clin Microbiol; 2008 Mar; 46(3):1060-6. PubMed ID: 18199779 [TBL] [Abstract][Full Text] [Related]
36. A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8 Li J; Chen S; Ge J; Lu F; Ren S; Zhao Z; Pu X; Chen X; Sun J; Gu Y Vaccine; 2017 Nov; 35(47):6459-6467. PubMed ID: 29029939 [TBL] [Abstract][Full Text] [Related]
37. Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer. Sharma C; Dey B; Wahiduzzaman M; Singh N Vaccine; 2012 Aug; 30(36):5417-24. PubMed ID: 22717329 [TBL] [Abstract][Full Text] [Related]
38. Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol. Freyschmidt EJ; Alonso A; Hartmann G; Gissmann L Antivir Ther; 2004 Aug; 9(4):479-89. PubMed ID: 15456078 [TBL] [Abstract][Full Text] [Related]
39. Design, Immune Responses and Anti-Tumor Potential of an HPV16 E6E7 Multi-Epitope Vaccine. de Oliveira LM; Morale MG; Chaves AA; Cavalher AM; Lopes AS; Diniz Mde O; Schanoski AS; de Melo RL; Ferreira LC; de Oliveira ML; Demasi M; Ho PL PLoS One; 2015; 10(9):e0138686. PubMed ID: 26390407 [TBL] [Abstract][Full Text] [Related]
40. In Silico Analysis of L1/L2 Sequences of Human Papillomaviruses: Implication for Universal Vaccine Design. Ghorban Hosseini N; Tebianian M; Farhadi A; Hossein Khani A; Rahimi A; Mortazavi M; Hosseini SY; Taghizadeh M; Rezaei M; Mahdavi M Viral Immunol; 2017 Apr; 30(3):210-223. PubMed ID: 28388355 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]